Overview
There have been major advancements in therapies and diagnostics for advanced-stage non-small-cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.
This webinar will feature interactive case-based panel discussions to review the state of the field for liquid biopsy in NSCLC and discuss the standard of care recommendations for a global audience that were proposed in the recently published IASLC consensus statement on liquid biopsy.
Related Files
January 11, 2022
10:00 AM EST/4:00 PM CET
At the end of the webinar, learners will be able to:
- Review the updated IASLC Consensus Recommendations for the Use of Liquid Biopsy in NSCLC
- Recognize clinical situations when liquid biopsy may improve lung cancer patient outcomes
This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, pulmonary medicine, medical oncology, thoracic surgery, radiation oncology, pathology, and cancer research/basic sciences.
Accreditation Statement
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Christian Rolfo, MD, PhD, MBA, Dr.hc.
- Consultant: EMD Serono, Pfizer, Mirati, Eisai, Daiichi Sankyo, Sanofi Genzyme-Regeneron
- Speakers Bureau: Astra Zeneca, Roche, COR2ED
David R. Gandara, MD
- Advisory Board: Roche Genentech, Merck, Novartis, Boehringer Ingelheim, Regeneron, Sanofi, Amgen
- Research Grant: Amgen, Astex, Genentech
- Consultant: Adagene, Astra Zeneca, IO Biotech, Guardant Health, Oncocyte
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
- Research Funding from Ineligible Companies: Amgen, Array, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, Takeda
- Honoraria for CME: BMS, MSD, Novartis, Takeda, Sanofi Genzyme
- Consultant: CADTH, EMD Serono, GlaxoSmithKline, Puma Biotechnology
Murry Wynes, PhD
- Nothing to Disclose
All other planners, reviewers and staff reported no relevant financial relationships.
All relevant financial relationships have been mitigated.
January 11, 2022
10:00 AM EST/4:00 PM CET
At the end of the webinar, learners will be able to:
- Review the updated IASLC Consensus Recommendations for the Use of Liquid Biopsy in NSCLC
- Recognize clinical situations when liquid biopsy may improve lung cancer patient outcomes
This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, pulmonary medicine, medical oncology, thoracic surgery, radiation oncology, pathology, and cancer research/basic sciences.
Accreditation Statement
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Christian Rolfo, MD, PhD, MBA, Dr.hc.
- Consultant: EMD Serono, Pfizer, Mirati, Eisai, Daiichi Sankyo, Sanofi Genzyme-Regeneron
- Speakers Bureau: Astra Zeneca, Roche, COR2ED
David R. Gandara, MD
- Advisory Board: Roche Genentech, Merck, Novartis, Boehringer Ingelheim, Regeneron, Sanofi, Amgen
- Research Grant: Amgen, Astex, Genentech
- Consultant: Adagene, Astra Zeneca, IO Biotech, Guardant Health, Oncocyte
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
- Research Funding from Ineligible Companies: Amgen, Array, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, Takeda
- Honoraria for CME: BMS, MSD, Novartis, Takeda, Sanofi Genzyme
- Consultant: CADTH, EMD Serono, GlaxoSmithKline, Puma Biotechnology
Murry Wynes, PhD
- Nothing to Disclose
All other planners, reviewers and staff reported no relevant financial relationships.
All relevant financial relationships have been mitigated.
Share
Participants
Christian Rolfo
MD, PhD, MBA, Dr.hc.
Professor and Assoc. Director for Clinical Research
Center for Thoracic Oncology/Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Mount Sinai Health System
Natasha B. Leighl
Lung Site Lead, Medical Oncology; OSI Pharmaceuticals Foundation; Adjunct Professor, IHPME, Professor, Department of Medicine Chair;
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
